PBAC's latest decision on Lanreotide acetate: Recommended with restriction (2017). Considered for Extension of listing for acromegaly and functional carcinoid tumour to allow prescription in community settings (previously hospital-only).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2005
Submissions
2
2005 → 2017
Eligible population
Adults aged 18 years or older with acromegaly (with persistent elevation of mean growth hormone levels >2.5 micrograms per litre and failure of other therapies) or functional carcinoid tumour (with intractable symptoms including ≥3 episodes per day of diarrhoea and/or flushing despite use of anti-histamines, anti-serotonin agents, and anti-diarrhoea agents).
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
Minor submission with no economic evaluation; cost-minimisation analysis not conducted. Financial impact presented as estimated net savings to PBS/RPBS.
Submission history
Jul 2005: Recommended with restriction · Restricted
Nov 2017: Recommended with restriction · Authority Required